At a glance
ClinicalIndex Comparison RecordN/ACompleted· 111 enrolled
Drug / intervention
non-interventionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Non-interventional Study To Observe The Safety And Efficacy Of Etanercept (Enbrel (Registered)) In Patients With Moderately Active Rheumatoid Arthritis In Every Day Clinical Practice In Austria
In Brief
An observational study evaluating non-intervention for Rheumatoid Arthritis. Completed, enrolled 111 participants across 10 sites.
Detailed Summary
This is a prospective non-interventional observational study to evaluate the treatment of moderately active RA patients in every day clinical practice in Austria. Patients will be observed over 52 weeks. The primary endpoint will be percentage of patients who reach CDAI remission after 24 weeks.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesAustria
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2012
First PostedJun 2013
Primary CompletionJan 2016
Study CompletionJun 2016
TodayJul 2026
First PostedJun 13, 2013
Enrollment StartDec 10, 2012
Primary CompletionJan 7, 2016
Study CompletionJun 14, 2016
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 13.1 years ago
Interventions
non-interventionother
observation of Etanercept treatment in moderately active RA patients in Austria. Etanercept treatment according to Austrian SmPC